I'm not suggesting anything of the sort. I believe their reasons for halting the trial are genuine and as stated. What I'm saying is, given those challenges which will not be resolved with the FDA any time soon, it is unlikely that PW will remain a priority going forward and will most likely be pursued by whoever acquires NEU.
Ann: Phase 2 trial shows significant improvements in Pitt Hopkins, page-146
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.27 |
Change
0.920(6.41%) |
Mkt cap ! $1.927B | |||
| Open | High | Low | Value | Volume |
| $14.35 | $15.27 | $14.35 | $8.720M | 579.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $15.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.27 | 3638 | 4 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |